GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review

GRAIL's Galleri multi-cancer early detection test is scheduled for a pivotal FDA advisory panel review in September 2026, marking the first premarket approval application for a multi-cancer detection test. The outcome could set a regulatory precedent impacting market expansion and reimbursement, with the test demonstrating promising clinical results and commercial growth.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.